Business Context and Reporting Period
Company: TNF Pharmaceuticals, Inc. (TNFA)
Filing Type: Form 8-K (Current Report)
Date of Report: November 25, 2024
Event: 2024 Annual Meeting of Stockholders held virtually on November 25, 2024.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity plan amendments. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders at the Annual Meeting. Total voting power present was 3,819,063 votes.
- Election of Directors: All seven nominees were elected for a one-year term.
- Nominees Elected: Mitchell Glass, Craig Eagle, Christopher C. Schreiber, Joshua Silverman, Jude Uzonwanne, Bill J. White, and Stephen Friscia.
- Voting Outcome: Significant support was recorded for all nominees, with "Votes For" ranging from approximately 2.96 million to 3.00 million per nominee. Broker non-votes totaled 778,079 for each director election.
- Equity Incentive Plan Amendment: Stockholders approved an amendment to the 2021 Equity Incentive Plan.
- Change: Increased the aggregate number of shares available for grant by 2,259,060 shares.
- New Total: 2,500,000 shares of Common Stock.
- Voting Outcome: 2,918,672 votes For; 116,753 votes Against; 5,559 votes Abstaining.
- Auditor Ratification: Stockholders ratified the appointment of Stephano Slack LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Voting Outcome: 3,738,231 votes For; 53,922 votes Against; 26,910 votes Abstaining.
- Adjournment Proposal: Approved a proposal to adjourn the meeting if necessary to solicit further proxies.
- Voting Outcome: 3,419,758 votes For; 373,008 votes Against; 26,297 votes Abstaining.
Capital Structure and Voting Rights
As of the record date (October 18, 2024), the voting composition included:
- Common Stock: 2,755,067 shares outstanding.
- Series D Preferred Stock: 72,992 shares (1,217 votes).
- Series F Preferred Stock: ~4,687 shares (~77,844 votes).
- Series F-1 Preferred Stock: 5,050 shares (2,241,455 votes).
- Series G Preferred Stock: 8,950 shares (3,972,481 votes).
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of specific risks beyond the standard incorporation by reference of the Proxy Statement. The primary focus is the successful execution of the Annual Meeting agenda.
Investor Verification Checklist
- Verify the final share count available under the amended 2021 Equity Incentive Plan (2,500,000 shares).
- Review the definitive Proxy Statement (Schedule 14A filed November 1, 2024) for detailed biographies of the re-elected directors and full terms of the Equity Incentive Plan.
- Confirm the impact of the significant voting power held by Series F-1 and Series G Preferred Stock on future corporate actions.
- Check subsequent filings for the appointment of Stephano Slack LLC as the auditor for the 2024 fiscal year.